# Diabetes Research Hub — Monitor Review

**Run date:** 2026-08-05 (automated, unattended)
**Reviewer:** Hub monitor (scheduled task)
**Bottom line:** No change since yesterday's review — the core data feeds are still frozen at **2026-07-17 (19 days old)**. Trials, PubMed, and the hub-monitor scan have not refreshed. The single useful action today is unchanged: **re-run the three baseline scripts** before trusting any "latest" figure. One genuinely new *external* development worth logging: Lilly's **retatrutide** posted positive Phase 3 topline (TRIUMPH-2/3) on 2026-07-23 — not yet in local data.

---

## File System Status

| File | Last modified | Age (days) | State |
|------|---------------|-----------|-------|
| `clinical_trials_latest.json` | 2026-07-17 | 19 | **STALE (>14d)** |
| `pubmed_recent_latest.json` | 2026-07-17 | 19 | **STALE (>14d)** |
| `hub_monitor_report.md` | 2026-07-17 | 19 | **STALE (>14d)** |
| `literature_gap_data.json` | 2026-07-18 | 18 | **STALE (>14d)** |
| `literature_gap_report.md` | 2026-08-04 | 1 | Fresh file, **stale inputs** |
| `citation_validation.json` | 2026-08-04 | 1 | Fresh |
| `pmid_verification.json` | 2026-08-04 | 1 | Fresh |
| `agent_state.json` | 2026-08-04 | 1 | Fresh |

**What's actually running vs. frozen:** the downstream/validation half of the pipeline is still executing daily (citation validation, PMID verification, gap-report regeneration, agent state — all 2026-08-04). The *upstream data pulls* are dead: no `clinical_trials_snapshot_*` or `pubmed_recent_snapshot_*` file exists after **2026-07-17**. So the daily gap report keeps re-analyzing the same 19-day-old PubMed pull — its header still reads "Date range: 2020/01/01 to **2026/07/17**." A fresh timestamp on `literature_gap_report.md` is **not** fresh evidence.

Caveat: this is the **second consecutive day** flagging the identical stall (see `monitor_report_2026-08-04.md`). Two automated warnings with no refresh suggests `baseline_clinical_trials.py` / `baseline_pubmed_alerts.py` are failing silently or no longer scheduled — worth a manual check of the cron/task and its logs, not just a re-run.

---

## Clinical Trial Changes

Snapshot frozen at 2026-07-17: **858 trials tracked.** Trial set in `clinical_trials_latest.json` is byte-identical to `clinical_trials_snapshot_2026-07-17.json` — **zero new/changed/removed trials since last review.**

Category counts: T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies (Ph2-3) 147 · Diabetes Technology 236 · Recently Completed w/ Results 321.
Status mix: 321 COMPLETED · 269 RECRUITING · 151 NOT_YET_RECRUITING · 110 ACTIVE_NOT_RECRUITING · 7 ENROLLING_BY_INVITATION. **46 trials are Phase 3 (or Phase 2/3) + RECRUITING.**

### Key Phase 3 trials from priority sponsors (status as of 07-17 — unchanged)

| NCT | Sponsor | Therapy | Phase | Status |
|-----|---------|---------|-------|--------|
| NCT06832410 | Vertex | **VX-880 / zimislecel** (T1D + kidney transplant) | 3 | RECRUITING |
| NCT04786262 | Vertex | **VX-880 / zimislecel** (T1D) | 3 | RECRUITING |
| NCT07222332 | Eli Lilly | **Baricitinib** — preserve beta-cell function, children | 3 | RECRUITING |
| NCT07222137 | Eli Lilly | **Baricitinib** — delay Stage 3 T1D | 3 | RECRUITING |
| NCT07564414 | Novo Nordisk | **CagriSema** + oral | 3 | RECRUITING |
| NCT06962280 | Eli Lilly | Tirzepatide in T1D (long-term) | 3 | ACTIVE_NOT_RECRUITING |
| NCT06260722 | Eli Lilly | **Retatrutide** vs semaglutide (TRANSCEND-T2D-2) | 3 | ACTIVE_NOT_RECRUITING |
| NCT06993792 | Eli Lilly | **Orforglipron** master protocol | 3 | ACTIVE_NOT_RECRUITING |

Highest-signal items (carried from prior reviews, still the frontier as of the local snapshot): Vertex zimislecel in **two recruiting Phase 3 trials** (cell-therapy cure at pivotal stage); Lilly **baricitinib — a repurposed JAK inhibitor — in two Phase 3 T1D-prevention trials**, directly relevant to Tier 1 Drug Repurposing.

### Recently posted results in local data (posted 2026, per 07-17 pull)

No trial in the snapshot carries `has_results=true`; the `results_posted` field flags these 2026 postings worth a look: NCT06010004 (Orforglipron long-term safety, Ph3 Lilly, 2026-06-30); Insulet Omnipod 5 + Libre 2 (2026-04-14); several DPP/behavioral and CGM studies (Johns Hopkins Afro-DPP 2026-04-22, UTSW remote CGM 2026-03-03). All previously available; nothing new since 07-17.

---

## PubMed Highlights

From the 07-17 pull: **158 unique papers**, 30-day lookback, 16 domains, 8 tracked therapies. **No new papers since** — no snapshot after 07-17.

### Cross-domain papers (highest priority — from the frozen pull)

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: a case of pediatric type 1 diabetes* — Diabetes AI/ML × Closed Loop AP × Health Equity (3 domains). Directly straddles two Tier 1 areas (AI/ML, Health Equity).
- **[42419792]** *Comparative effects of drugs for adults with overweight or obesity: network meta-analysis* — orforglipron × retatrutide × CagriSema (3 tracked therapies).
- **[42411999]** *Type 1 Diabetes Driven by Residual Recipient T Cells After HCT: case report* — Stem Cell Cure × Immunotherapy.
- **[42437645]** orforglipron GLP-1R co-folding MD study — GLP-1 Pharmacogenomics × orforglipron.

### Tracked-therapy mentions (07-17 pull)

dapagliflozin 52 · orforglipron 10 · CagriSema 6 · retatrutide 4 · teplizumab 4 · icodec 3 · baricitinib 2 · **zimislecel 0**. Note the persistent zimislecel zero despite two active Phase 3 trials — likely a terminology gap (papers still say "VX-880" / "islet cell therapy"); worth widening the PubMed query alias list.

---

## Gap Analysis Summary

Top intersections (BRONZE, from `literature_gap_report.md`; underlying data 07-17, requires expert confirmation):

1. **Treg / CAR-T × Neuropathy** — gap 100, 0 joint pubs
2. **Beta Cell Regen × Health Equity** — gap 100, 0 joint pubs
3. **Treg / CAR-T × Health Equity** — gap 100, 0 joint pubs
4. **Glucokinase × Health Equity** — gap 100, 0 joint pubs
5. **Gene Therapy × LADA** — gap 100, 0 joint pubs

**Alignment with Tier 1 contribution areas (Research Doctrine):** four of the top five bridge into **Health Equity / Epidemiological Analysis (Tier 1 #6)** — Beta Cell Regen, Treg/CAR-T, Glucokinase, and Drug Repurposing each paired with Health Equity all score 100 with zero joint publications. This is the same "equity analysis of emerging cell/immune therapies is absent" pattern the doctrine calls high-value. Drug Repurposing × Health Equity (Tier 1 #4 × #6) is a double-Tier-1 intersection and the most defensible synthesis target once data is refreshed. Caveat: zero joint pubs can be terminology mismatch, not a true void — verify with combined-term PubMed searches before committing.

---

## Breaking News (web check, last ~2 weeks)

- **[Certain] Retatrutide Phase 3 topline — TRIUMPH-2 (T2D + obesity) & TRIUMPH-3 (severe obesity + CVD), announced 2026-07-23.** Up to 20.8% mean weight loss (TRIUMPH-2) and 22.6% (TRIUMPH-3) at 80 weeks, with A1C reductions ~1.5%. Lilly plans FDA submission Q1 2027. Source: Lilly investor release / PR Newswire. **This postdates the 07-17 local pull and involves a tracked therapy — it is not yet in any local file.** TRANSCEND-T2D-2 (NCT06260722) is the T2D arm already tracked; TRIUMPH-2/3 are the obesity-program pivotals.
- **[Certain] Teplizumab (Tzield) — FDA accelerated approval for pediatric Stage 3 T1D (ages 8–17), 2026-06-12** (PROTECT trial, n=328). Logged for completeness, but this predates the local 07-17 snapshot and is **not new this cycle** — no action beyond confirming it's reflected once trials refresh.
- No other items rise above routine. Zimislecel/VX-880 regulatory submission still described as "expected 2026" with the 5-year FORWARD Phase 3 ongoing — no filing confirmed yet.

---

## Recommended Actions

1. **Diagnose the stalled pipeline, don't just re-run it.** Two straight days of the same 07-17 freeze means the upstream pulls are likely failing silently or unscheduled. Check the scheduler and script logs for `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py`, then:
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   - `python hub_monitor.py`
2. **Re-run gap analysis only after the PubMed pull succeeds** (`python project1_literature_gap_analysis.py`). Regenerating it against stale input — as happened 08-03 and 08-04 — produces a fresh file with 19-day-old evidence.
3. **Log the retatrutide TRIUMPH-2/3 topline (2026-07-23)** in `Diabetes_Research_Tracker.xlsx` under the retatrutide program — Phase 3 obesity pivotals, FDA submission planned Q1 2027. Evidence level: company topline (not peer-reviewed); mark accordingly per Research Doctrine.
4. **Widen the zimislecel PubMed alias set** to include "VX-880" and "islet cell therapy" — the current query returns 0 hits despite two active Phase 3 programs, which is almost certainly a terminology miss rather than a true absence.
5. **Prioritize Drug Repurposing × Health Equity** as the next synthesis target when data is current — it is the strongest double-Tier-1 gap; verify the 0-joint-pub finding with combined-term searches first.

---

*Generated by Diabetes Research Hub monitor — automated run 2026-08-05. Read-only review; no existing files modified. Evidence levels per Research Doctrine v1.0.*
